Brandywine Global Investment Management LLC Boosts Stake in Icon Plc $ICLR

Brandywine Global Investment Management LLC raised its position in Icon Plc (NASDAQ:ICLR) by 5.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 399,813 shares of the medical research company’s stock after buying an additional 22,393 shares during the period. Brandywine Global Investment Management LLC’s holdings in Icon were worth $71,681,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of ICLR. Toth Financial Advisory Corp bought a new position in shares of Icon during the 4th quarter valued at approximately $27,000. Ameriflex Group Inc. bought a new position in shares of Icon during the 3rd quarter valued at approximately $33,000. Johnson Financial Group Inc. bought a new position in shares of Icon during the 3rd quarter valued at approximately $71,000. Quadrant Capital Group LLC bought a new position in shares of Icon during the 3rd quarter valued at approximately $78,000. Finally, Geneos Wealth Management Inc. grew its position in shares of Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 56 shares during the period. 95.61% of the stock is owned by institutional investors.

Icon Stock Performance

NASDAQ ICLR opened at $149.45 on Monday. Icon Plc has a 1 year low of $66.57 and a 1 year high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.10 and a quick ratio of 1.10. The stock has a market capitalization of $11.44 billion, a PE ratio of 24.26, a P/E/G ratio of 11.81 and a beta of 1.26. The company’s 50 day simple moving average is $117.51 and its two-hundred day simple moving average is $140.74.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, May 27th. The medical research company reported $2.21 earnings per share (EPS) for the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion for the quarter. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. Analysts predict that Icon Plc will post 9.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. TD Cowen increased their target price on shares of Icon from $120.00 to $164.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Rothschild & Co Redburn set a $100.00 target price on shares of Icon and gave the company a “neutral” rating in a research report on Tuesday, February 17th. Weiss Ratings downgraded shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Barclays increased their target price on shares of Icon from $120.00 to $150.00 and gave the company an “equal weight” rating in a research report on Friday, May 29th. Finally, BMO Capital Markets increased their target price on shares of Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a research report on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $156.44.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.